SPRO

Spero Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-26

Figures on this page computed 2026-11-08 13:03 UTC

Last close

1.07USD

Market data, 2026-11-04

SPRO: weekly closes from 2.79 on 2026-05-15 to 1.07 on 2026-11-04, a move of -61.6%. Prices in USD.

Weekly closes, 2026-05-15 to 2026-11-04

Over that span: -61.6%

Except where said otherwise: 10-K for 2025, filed 2026-03-26

6.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-26
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
The filing itself
12.8%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.06x

-0.20x

n/a

0.15x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

3 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-26

Sales2.06x
Its own average over 10 years, 32.4M.
Profit-0.20x
Its own average over 10 years, -41.9M.
Free cash flown/a
Its own average over 5 years, -49.5M.
Debtn/a
Its own average over 0 years.
Price0.15x
Its own average over 10 years, 7. Market data, 2026-11-04

Profit is furthest from its own average, at -0.20 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	n/a
2017-12-31	590.7	n/a
2018-12-31	1,183.9	n/a
2019-12-31	5,417.0	n/a
2020-12-31	2,785.1	n/a
2021-12-31	5,449.6	100.0
2022-12-31	15,972.8	121.7
2023-12-31	30,979.4	171.5
2024-12-31	14,321.5	174.9
2025-12-31	19,940.9	191.1

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-126192
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-126192
Reported in: USD

The filing itself

Figures behind the shape

Growth

48.3%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate48.3%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income112.5%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

14.5%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
The filing itself
Return on equity14.5%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
The filing itself
Return on assets12.4%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
The filing itself

Margins

9.4%

wider is higher, placed against 4,336 companies as of 2026-11-07

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Operating margin9.4%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Net margin12.8%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Free cash flow marginn/a
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself

Price

6.9x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earnings6.9x
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-26
The filing itself
Price to book1.0x10-Q for 2025, filed 2026-08-12
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-346795
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-12
- computed
- 10-K for 2025, filed 2026-03-26
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
- 10-K for 2025, filed 2026-03-26
The filing itself
Price to sales ratio0.9x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself

Safety

7.59

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-12
The filing itself
Current ratio7.5910-Q for 2025, filed 2026-08-12
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001193125-26-346795
Reported in
USD
- 10-Q for 2025, filed 2026-08-12
- 10-Q for 2025, filed 2026-08-12
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Altman Z-Score-3.19
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-26
- Computed from the 10-K for 2025, filed 2026-03-26
- Computed from the 10-K for 2025, filed 2026-03-26
- Computed from the 10-K for 2025, filed 2026-03-26
- Computed from the 10-K for 2025, filed 2026-03-26

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001193125-26-126192
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- Computed from the 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.